Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for a new indication of Trastuzumab rezetecan, with priority review granted. The application seeks approval for Trastuzumab rezetecan, in combination with or without pertuzumab, for the first‑line treatment of patients with locally advanced or metastatic HER2‑positive breast cancer – a potential expansion of the antibody‑drug conjugate (ADC) from the post‑progression into the front‑line setting.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Filing Type | New Drug Application (NDA) for a new indication – accepted |
| Review Designation | Priority review granted |
| Product | Trastuzumab rezetecan – proprietary in‑house‑developed anti‑HER2 ADC |
| Proposed Indication | First‑line treatment of patients with locally advanced or metastatic HER2‑positive breast cancer, in combination with or without pertuzumab |
| Announcement Date | 29 Oct 2026 |
| Review Decision Date | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Trastuzumab rezetecan, a proprietary antibody‑drug conjugate (ADC) targeting HER2, developed in‑house by Hengrui.
- Mechanism of Action: The ADC binds to HER2‑expressing tumor cells and undergoes endocytosis; inside the tumor cell lysosome, the cytotoxic payload is released through protease cleavage, inducing cell cycle arrest and triggering tumor cell apoptosis.
- Combination Strategy: The first‑line application covers use with or without pertuzumab, offering flexibility to pair the ADC with established HER2‑targeted antibody backbone therapy in earlier‑line disease.
- Approval Track Record: The drug has already been approved for three indications in China, spanning breast, lung, and colorectal cancers – a breadth that underscores the platform’s tumor‑agnostic HER2 targeting.
Currently Approved Indications in China
| # | Indication | Setting |
|---|---|---|
| 1 | Adult patients with unresectable, locally advanced, or metastatic non‑small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations | After at least one prior systemic therapy |
| 2 | Adult patients with locally advanced or metastatic HER2‑positive breast cancer | After one or more prior anti‑HER2 therapies |
| 3 | Adult patients with HER2‑positive colorectal cancer | After failure of prior oxaliplatin, fluorouracil, and irinotecan treatment |
Market Impact & Outlook
- Front‑Line Ambition: Acceptance with priority review moves Trastuzumab rezetecan toward potentially displacing or complementing the current standard of care in first‑line HER2‑positive metastatic breast cancer – the largest and most commercially significant HER2 market.
- Accelerated Timeline: The priority review designation typically shortens NMPA technical evaluation time, bringing a potential approval decision closer for patients with limited first‑line options.
- Fourth‑Indication Momentum: Approval would mark the fourth indication for the ADC in China, extending Hengrui’s fully in‑house oncology franchise across breast, lung, and colorectal tumors.
- Competitive Positioning: With global ADC competition intensifying in HER2‑positive breast cancer, an earlier‑line label would strengthen Trastuzumab rezetecan’s position against both imported ADCs and domestic rivals in China’s high‑volume breast cancer market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding NMPA review timelines, approval outcomes, and commercialization of Trastuzumab rezetecan. Actual results may differ materially due to risks including regulatory review decisions, additional data requirements, competitive dynamics, and market adoption. The NDA acceptance and priority review designation do not guarantee final approval.-Fineline Info & Tech
